3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Melanoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Ganglioneuroblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
36
Nivolumab
32
Bevacizumab
13
Sunitinib
10
Ipilimumab
10
aldesleukin
7
Interleukin-2
7
Axitinib
7
lenvatinib
6
cabozantinib
6
Paclitaxel
6
Everolimus
6
Docetaxel
6
Cyclosporine
6
Cyclophosphamide
6
fludarabine phosphate
5
Sorafenib
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
fludarabine
4
cemiplimab
4
belzutifan
4
Whole-Body Irradiation
4
Radiosurgery
4
Interferon-alpha
4
Cetuximab
4
durvalumab
3
bempegaldesleukin
3
avelumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Renal Cell
×
Colony-Stimulating Factors
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled